Despite the development of the novel Bruton tyrosine kinase inhibitor ibrutinib, mantle cell lymphoma (MCL) remains an incurable B-cell non-Hodgkin lymphoma. This evidence concerns the gene BTK and B-cell non-Hodgkin lymphoma.